Characterization and tentative identification of new flunitrazepam metabolites in authentic human urine specimens using liquid chromatography‐Q exactive‐HF hybrid quadrupole‐Orbitrap‐mass spectrometry (LC‐QE‐HF‐MS). (13th August 2019)

• Record Type: Journal Article
• Authors: Qin, Shiyang; Xin, Guobin; Wang, Yuanfeng; Qiao, Jing; Zhang, Wenfang; Xu, Duoqi; Xu, Zizhen; Liu, Yongtao; Zhang, Ying; Lu, Jianghai
• Is Part Of: Journal of mass spectrometry. Volume 54:Number 8(2019)
• Page Start: 704
• Page End: 715
• Publication Date: 2019-08-13
• Subjects: chemical structural identification -- flunitrazepam -- human urine -- liquid chromatography‐Q exactive‐HF hybrid quadrupole‐Orbitrap‐mass spectrometer -- metabolic profiles; Mass spectrometry -- Periodicals; 543.65
• DOI: 10.1002/jms.4383
• Languages: English
• ISSNs: 1076-5174

Abstract

Abstract: Flunitrazepam (FNZ) is a potent hypnotic, sedative, and amnestic drug used to treat severe insomnia. In our recent study, FNZ metabolic profiles were investigated carefully. Six authentic human urine samples were purified using solid phase extraction (SPE) without enzymatic hydrolysis, and urine extracts were then analyzed by liquid chromatography‐Q exactive‐HF hybrid quadrupole‐Orbitrap‐mass spectrometry (LC‐QE‐HF‐MS), using the full scan positive ion mode and targeted MS/MS (ddms2) technique to make accurate mass measurements. There were 25 metabolites, including 13 phase I and 12 phase II metabolites, which were detected and tentatively identified by LC‐QE‐HF‐MS. In addition, nine previously unreported phase II glucuronide conjugates and four phase I metabolites are reported here for the first time. Eight metabolic pathways, including N‐reduction and O‐reduction, N‐glucuronidation, O‐glucuronidation, mono‐hydroxylation and di‐hydroxylation, demethylation, acetylation, and combinations, were implicated in this work, and 2‐O‐reduction together with dihydroxylation were two novel metabolic pathways for FNZ that were identified tentatively. Although 7‐amino FNZ is widely considered to be the primary metabolite, a previously unreported metabolites (M12) can also serve as a potential biomarker for FNZ misuse.